Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

Exit

PublicOTC:BCLI
Raised
Post IPO Valuation

General Information

Websitebrainstorm-cell.com
Twitter@BrainStormCell
CategoryBioTech
Phone646-666-3188
Emailinfo@brainstorm-c...
Employees
Founded2004

Offices

New York, USA
605 Third Avenue
34th Floor
New York, NY, 10158
USA

People

CFO
President & CEO

Funding

TOTAL $1.01M
FUNDING TOTAL $1.01M
Seed, 7/2012
$207k
Grant, 12/2013
$800k

Tags

BrainStorm Cell Therapeutics

BrainStorm Cell Therapeutics (OTC.QB: BCLI) is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease), Multiple Sclerosis (MS) and Parkinson’s Disease (PD).

NurOwn™ , our proprietary, first-of-its-kind technology for the propagation and differentiation of autologous Mesenchymal Stem Cells (MSCs) into NeuroTrophic Factor (NTF)-secreting cells and their transplantation at or near the site of damage, offers the hope of conquering neurodegenerative diseases.

We are currently conducting a Phase IIa ALS clinical trial with NurOwn at the Hadassah University Medical Center in Jerusalem. In this safety and preliminary efficacy trial, 12 patients will receive combined intramuscular and intrathecal administration of NurOwn cells in three cohorts with increasing doses. The study participants will be followed for three to six months after transplantation.

The company also plans to begin a Phase II clinical trial in the USA in 2013, pending FDA approval.

In February 2011, NurOwn was granted Orphan Drug designation by the FDA.

Over 20 publications in leading scientific journals demonstrating NurOwn’s mechanism of action, pharmacology and in vivo efficacy have been published by the scientific team.

Recent Milestones

Videos

Screenshots

BrainStorm Cell Therapeutics screenshot
Above: HomePage
Uploaded: 7/31/13

Stock Price

Sources

  1. SEC (sec.gov) [edit]
  2. BrainStorm Receives $800,000 Non-Dilutive Grant from Israel’s Office of the Chief Scientist (jewishbusinessnews.com) [edit]
Edit This Page
Last Edited 12/13/13

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize »

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy